The ethical plausibility of the ‘Right To Try’ laws
Critical Reviews in Oncology/Hematology
© 2017 Elsevier B.V. All rights reserved.
Reason for embargo
‘Right To Try’ (RTT) laws originated in the USA to allow terminally ill patients to request access to early stage experimental medical products directly from the producer, removing the oversight and approval of the Food and Drug Administration. These laws have received significant media attention and almost equally unanimous criticism by the bioethics, clinical and scientific communities. They touch indeed on complex issues such as the conflict between individual and public interest, and the public understanding of medical research and its regulation. The increased awareness around RTT laws means that healthcare providers directly involved in the management of patients with life-threatening conditions such as cancer, infective, or neurologic conditions will deal more frequently with patients’ requests of access to experimental medical products. This paper aims to assess the ethical plausibility of the RTT laws, and to suggest some possible ethical tools and considerations to address the main issues they touch.
This paper was funded by the European School of Oncology.
This is the author accepted manuscript. The final version is available from Elsevier via the DOI in this record.
Vol. 122, pp. 64-71